We are live on ! Find out more
LIXTW

Lixte Biotechnology Warrants
LIXTW

Delisted

LIXTW was delisted on the 26th of November, 2025.

Back to rankings

3 hedge funds and large institutions have $3.98K invested in Lixte Biotechnology Warrants in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.34% less ownership

Funds ownership: 6.19% → 3.85% (-2.3%)

40% less funds holding

Funds holding: 5 → 3 (-2)

55% less capital invested

Capital invested by funds: $8.88K → $3.98K (-$4.9K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Holders
3
Holders Change
-2
Holders Change %
-40%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
EFG
Ethos Financial Group
Pennsylvania
-$3K
2
UBS Group
UBS Group
Switzerland
-$245
3
Citadel Advisors
Citadel Advisors
Florida
-$189
4
WAM
Warberg Asset Management
Illinois
-$93
5
CS
Clear Street
New York
-$29

LIXTW Hedge Fund Activity: Q3 2024 in Review

3 of the 6,979 institutional investors tracked by Wall St. Rank reported a position in Lixte Biotechnology Warrants (LIXTW) for Q3 2024, worth a combined $3.98K — down 55% from $8.88K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of LIXTW and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 0 added.

The largest seller was Ethos Financial Group, exiting entirely with an estimated $3K sold.

  • 3 institutional investors held Lixte Biotechnology Warrants (LIXTW) as of Q3 2024, down from 5 in Q2 2024.
  • Funds reported $3.98K of Lixte Biotechnology Warrants stock for Q3 2024, down 55% quarter-over-quarter.
  • 0 funds opened new Lixte Biotechnology Warrants positions in Q3 2024 and 2 closed out, a net change of -2 holders.
  • The largest Lixte Biotechnology Warrants seller in Q3 2024 was Ethos Financial Group, an estimated $3K sold.

Based on aggregated 13F filings for Q3 2024.